News

Filter News By

Clear Filters

  1. FDA Approves Kalydeco® for Children With CF Ages 1 to 2

    August 15, 2018

    Today, the U.S. Food and Drug Administration approved the use of ivacaftor (Kalydeco®) for children with cystic fibrosis ages 1 to 2 who have at least one mutation that is responsive to ivacaftor.

    Topics:

  2. FDA Expands Use of Orkambi® to Children With CF Ages 2 to 5

    August 7, 2018

    The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.

  3. CF Foundation Responds to Final Short-Term, Limited-Duration Health Insurance Rule

    August 2, 2018

    Yesterday, the U.S. Department of Health and Human Services finalized a rule expanding short-term, limited-duration insurance plans -- threatening access to adequate, affordable coverage for people with cystic fibrosis who rely on the individual marketplace.

  4. Drug Shows Promise in Reducing Inflammation in People With Cystic Fibrosis

    August 2, 2018

    Celtaxsys Inc. reported promising results today from an early stage clinical trial of a potential anti-inflammatory drug for people with cystic fibrosis.

  5. CF Teen Advocates Visit Capitol Hill for 10th Annual Teen Advocacy Day

    July 5, 2018

    More than 200 advocates from 32 states traveled to Washington, D.C., on June 28 for the Cystic Fibrosis Foundation’s 10th annual Teen Advocacy Day, which enabled teens to meet with their elected officials on Capitol Hill to fight for access to high-quality, specialized care for their friends and loved ones living with CF.

    Topics:

  6. Choate Construction Makes Corporate Impact Through 9th Annual Cars & ‘Q for the Cause Fundraiser

    June 20, 2018

    Choate Construction’s 9th annual Cars & ‘Q for the Cause raised over $435,400 for the Cystic Fibrosis Foundation, serving as a role model for corporations looking to integrate philanthropy into their business model.

    Topics:

More Posts View All Posts

Follow Us On